Mr. Rene Goehrum reports

BIOSYENT SCHEDULES FOURTH QUARTER AND FULL YEAR 2023 EARNINGS RELEASE FOR MARCH 13, 2024

BioSyent Inc. will report its financial results for the three months and full year ended Dec. 31, 2023, on Wednesday, March 13, after market hours. A presentation on the company's fourth quarter and full year 2023 results by Rene Goehrum, BioSyent president and chief executive officer, will also be available on the company's website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its community, specialty and international business units.

We seek Safe Harbor.